Pre-hospital Administration of Thrombolytic Therapy With Urgent Culprit Artery Revascularization

Overview

The PATCAR study has been designed to test the hypothesis that the strategy of pre-hospital use of a "clot busting" (thrombolytic) drug followed with emergent heart catheterization including stenting of the problematic coronary artery, will result in a lower mortality and reduced repeat heart attack rates. Early identifying and treating heart attacks patients prior to the arriving at the hospital, in those patients who qualify for the "clot busting" drugs will lower the size of the heart attack damage. This smaller heart attack will lead to fewer problems with less repeat heart attacks and death in the future.

Full Title of Study: “PATCAR Pilot Trial: A Phase 4 Study, Pre-hospital Administration of Thrombolytic Therapy With Urgent Culprit Artery Revascularization”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: December 2009

Detailed Description

To demonstrate feasibility of the project in a pilot trial we plan to enroll up to 500 patients to pre-hospital thrombolysis/clot busting followed by emergent catheterization and stenting of the problematic or culprit artery. This will comprise an EMS system capable of performing pre-hospital ECGs followed by emergent transportation to a Level I Cardiovascular Center where the patients will be taken to urgent cardiac catheterization and emergent stenting of the culprit artery. Patients identified as having typical symptoms of acute MI and an ECG consistent with acute ST elevation MI will be screened in the field by paramedics or in the spoke hospitals by the ED attending physicians using the screening form. Verbal Consent will be obtained for receiving acute therapy for their MI as outlined in the protocol. After therapy is initiated in the field or at the spoke hospital, the patients will be transported as quickly as possible to the receiving Level I Cardiovascular Center (Hub Hospital). The ED personnel in the Level I Cardiovascular Center will have activated the Interventional Cardiovascular Team and the Cath Lab personnel after having received the initial qualifying transmitted ECG. Once the patient arrives, informed consent will be obtained by the ED investigator and/or in-house Cardiology fellow for enrollment in the PATCAR Trial. Thrombolytic ineligible patients will also be collect for this study and also go directly to the Cath Lab for PCI. Study coordinators will enter the data into the Case Report Forms and forward the completed forms to Westat-ALA for data capture in the database. In addition to the qualifying ECG, ECG's will be obtained at hospital discharge/transfer. All patients will follow the current standard of care for STEMI/heart attacks patients. Patients will have a Cardiac MRI done on day 3 or 5 of their hospital stay, to measure the size and amount of damage the heart suffered as a result of their Heart attack.

Interventions

  • Drug: Reteplase 10 Units (U) plus a second dose of reteplase 10 U
    • Thrombolytic-clot busting drug Retavase IV Bolus, 10 U followed by a second 10U dose
  • Drug: Reteplase 10 U
    • Thrombolytic-clot busting drug Retavase IV Bolus in one 10U dose
  • Procedure: Urgent Percutaneous Coronary Intervention (PCI)
  • Procedure: Primary Percutaneous Coronary Intervention (PCI)

Arms, Groups and Cohorts

  • Experimental: Group A: Full dose pre-hospital fibrinolysis
    • Patients transported by participating EMS units and that were fibrinolytic eligible and treated with full dose, pre-hospital fibrinolysis with reteplase (treated in the ambulance with 10 units reteplase and randomized to a second 10-unit dose of reteplase).
  • Experimental: Group B: Half dose pre-hospital fibrinolysis followed by urgent PCI
    • Patients transported by participating EMS units and that were fibrinolytic eligible and treated with a half dose pre-hospital fibrinolysis with reteplase (treated in the ambulance with 10 units reteplase) and randomized to urgent catheterization with percutaneous coronary intervention (PCI).
  • Active Comparator: Group C: Fibrinolytic ineligible patients receiving primary PCI
    • Patients transported by participating EMS units and that were fibrinolytic ineligible and treated with primary PCI alone and that were prospectively analyzed for comparison.
  • Active Comparator: Group D: Patients transferred in and treated with primary PCI
    • Patients not transported by participating EMS units but were transferred in and treated with primary PCI alone and that were prospectively analyzed for comparison.

Clinical Trial Outcome Measures

Primary Measures

  • Mortality at 30 Days
    • Time Frame: 30 day

Secondary Measures

  • Infarction Size as Measured by Cardiac Magnetic Resonance Imaging (MRI)
    • Time Frame: 1 year
  • Reduction in Time From Onset of Pain to Reperfusion
    • Time Frame: 1 year
  • Angiographic Documentation of Reperfusion
    • Time Frame: 1 year
  • Electrocardiogram (ECG) ST Segment Elevation Recovery
    • Time Frame: 1 year

Participating in This Clinical Trial

Inclusion Criteria

1. Ischemic discomfort (squeezing, crushing, or pressure, sub-sternal, unrelated to breathing or movement), epigastric discomfort or pre-syncopal symptoms with diaphoresis, lasting > 30 minutes. 2. ST elevation > 0.1 mV in 2 or more contiguous limb leads or > 0.2 mV in 2 or more contiguous pre-cordial leads. 3. Less than 6 hours after onset of sustained chest pain. 4. Age 18 years or older. Exclusion Criteria:

1. Chest pain described as ripping or tearing, radiating to the back and/or down the leg, and/or systolic blood pressure > 15 mmHg difference in each arm. 2. Suspected cocaine or amphetamine use within previous 3 days. 3. Known or suspected pregnancy. 4. Cardiac arrest requiring intubation. 5. Cardiac arrest requiring greater than 20 minutes CPR. 6. Coronary intervention (PTCA/stent/CABG) within previous 4 weeks.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • The University of Texas Health Science Center, Houston
  • Provider of Information About this Clinical Study
    • Principal Investigator: Richard Smalling, Professor – Internal Medicine, Cardiology – The University of Texas Health Science Center, Houston
  • Overall Official(s)
    • Richard W. Smalling, MD, PhD, Principal Investigator, The University of Texas Health Science Center, Houston

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.